Evidence map›Paper›PMID 40560021›Full record

ArticlePharmacy (Basel, Switzerland)2025

Adherence and Cost-Utility Analysis of Antiretroviral Treatment in People Living with HIV in a Specialized Clinic in Mexico City.

Ivo Heyerdahl-Viau, Francisco Javier Prado-Galbarro, Santiago Ávila-Ríos, Osmar Adrian Rosas-Becerril, Raúl Adrián Cruz-Flores, Carlos Sánchez-Piedra, Juan Manuel Martínez-Núñez

Abstract read
In one paragraph

Article in Pharmacy (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ivo Heyerdahl-ViauMaestría en Ciencias Farmacéuticas, Universidad Autónoma Metropolitana Unidad Xochimilco, Mexico City 04960, Mexico.
Francisco Javier Prado-GalbarroHospital Infantil de México "Federico Gómez", Mexico City 06720, Mexico.ORCID 0000-0002-1474-5228
Santiago Ávila-RíosCentro de Investigación en Enfermedades Infecciosas (CIENI), Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.
Osmar Adrian Rosas-BecerrilDepartment of Biological Systems, Universidad Autónoma Metropolitana Unidad Xochimilco, Mexico City 04960, Mexico.
Raúl Adrián Cruz-FloresClínica Especializada Condesa Iztapalapa, Mexico City 09730, Mexico.
Carlos Sánchez-PiedraHealth Technology Assessment Agency (AETS), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.ORCID 0000-0001-5420-7347
Juan Manuel Martínez-NúñezDepartment of Biological Systems, Universidad Autónoma Metropolitana Unidad Xochimilco, Mexico City 04960, Mexico.ORCID 0000-0001-6316-5054

Funding

Secretaría de Ciencia, Humanidades, Tecnología e Innovación, SECIHTI (formerly called CONAHCYT) 4013419
6 · The paper itself

Abstract

This study aimed to evaluate the therapeutic adherence to antiretroviral therapy (ART) and the cost of care for people living with HIV (PLwHIV) in the Condesa Specialized Clinics (CSCs). A cross-sectional observational study was conducted using the Adherence Follow-Up Questionnaire developed by The AIDS Clinical Trials Group (ACTG) to measure adherence in 261 PLwHIV. An economic Markov model was developed to simulate clinical outcomes, health costs, and quality-adjusted life years (QALYs) over a 5-year horizon from the CSC perspective. The mean adherence index was 89.97, and 59% of the surveyed PLwHIV were non-adherent, but more than 95% of the population had an undetectable viral load, suggesting that ART remains effective in achieving clinical goals, even under suboptimal adherence conditions. More than half of the surveyed PLwHIV (60.54%) stated that they had stopped taking their ART at some point, and the three most frequent causes were forgetting (49.37%), being away from home (45.57%), and having a change in their daily routine (25.95%). The economic model showed a cumulative cost per PLwHIV of USD 8432 and 3.80 QALYs (USD 2218/QALYs), which is below the threshold of willingness to pay in Mexico (USD 13,790/QALY). These findings provide valuable information to guide public health decisions and resource allocation in HIV management in Mexico.

Indexed as

antiretroviralCD4 cell countHIV healthcare costsHIV treatment adherenceviral suppression

Identifiers

PMID40560021
PMCPMC12196694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.